HELPCybin D/B/A Helus Pharma
Price
+76%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growing in the filings, the market undecided.
Cybin Inc. (the “Company” or the “Registrant”) is a Canadian issuer that is permitted, under the multijurisdictional disclosure system adopted in the United States, to prepare this Annual Report on Form 40-F (this “Annual Report”) pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in accordance with Canadian disclosure requirements, which are different from those of the United States.
In the company’s own words · 40-F filed Jun 29, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was CAD 8.3M (+1239% year on year) and net income −CAD 113M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.